Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02660424 · ClinicalTrials.gov registry record · Phase 2

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

A Phase 2 study of Osteoarthritis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
124
Enrollment target
12
Study locations

NCT02660424 is a Phase 2 study of Osteoarthritis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 124 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02660424, a Phase 2 study of Osteoarthritis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
124 participants
Enrollment target
12
Study locations

Study Summary

The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG VX-150

Study Locations (12)

California

  • - San Diego

Florida

  • - West Palm Beach

Georgia

  • - Marietta

Indiana

  • - Valparaiso

Kansas

  • - Wichita

Michigan

  • - Bay City

Nevada

  • - Las Vegas

New York

  • - Hartsdale

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2015-12
Est. Completion 2016-09
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

What the Registry Record Tells You About NCT02660424

The ClinicalTrials.gov registry entry for NCT02660424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (85% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02660424 reports 12 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02660424 about?

NCT02660424 is a clinical study titled "A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee". The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain

What is the current status of trial NCT02660424?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-12. Estimated completion is 2016-09.

What conditions does trial NCT02660424 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT02660424?

The interventions under investigation include: Placebo (DRUG), VX-150 (DRUG).

Who is sponsoring clinical trial NCT02660424?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02660424 being conducted?

This trial has 12 study locations across California, Florida, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.